Revenio Group Oyj - Company Announcement

Revenio Group Corporation: Revenio has begun to commercialize technology for the screening, diagnosis and monitoring of asthma

Revenio Group Corporation Stock Exchange Release, February 2, 2015 at 9:00 am

Revenio has begun to commercialize technology for the screening, diagnosis and
monitoring of asthma

Revenio Group Corporation has signed a license agreement with Tide Medical Oy
concerning a patented invention relating to the diagnosis of asthma. This
agreement allows Revenio to use this invention as a basis on which to develop
and commercialize products relating to the screening, diagnosis, monitoring and
treatment of asthma. The current outlook indicates that it will take several
years before these products become commercially significant for the company."The diagnosis of asthma in infants and young children has been particularly
challenging. Traditional spirometry requires procedures that are unsuitable for
examining lung functionality in this target group. The agreement that we have
just signed will enable us to productize the patented technology developed by a
research group from Tampere University of Technology. Our goal is to provide
physicians with an accurate, user-friendly and mobile device that will make it
considerably easier to screen for, diagnose and monitor asthma in infants and
young children. We can play a part in improving quality of life for young
patients and significantly speeding up diagnoses. In the longer term, we aim to
expand our product portfolio for the screening, diagnosis and monitoring of
asthma to cover adults and those suffering from chronic obstructive pulmonary
disease," says the Revenio Group's President & CEO Olli-Pekka Salovaara."For us, healthcare technology will increasingly mean screening-related
products. Licensing is an extremely fast and cost-effective way to establish a
foundation for future growth in the Revenio Group. The license agreement we have
just signed with Tide Medical enables us to use relatively advanced,
commercializable and productizable technology. The costs of licensing are
moderate compared to those of an acquisition, and we're paying the developers
for actual net sales, not a vision," Olli-Pekka Salovaara continues.

As part of the licensing agreement, Ville-Pekka Seppä, D.Sc. (Tech.), who has
been developing the procedure, will join the Revenio Group Corporation's
subsidiary Revenio Research Oy as the product development manager in charge of
developing products in accordance with the license agreement.

Asthma is one of the most common chronic disease in the world with over 300
million sufferers. In Finland, 9.4% of the population suffers from asthma.

Revenio Group Corporation
Olli-Pekka Salovaara
Prsedent & CEO

Further information:
President & CEO Olli-Pekka Salovaara, tel. +358 (0)40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is tonometers. The
Revenio Health Tech segment comprises the business operations of Icare Finland
Oy and Oscare Medical Oy, which specializes in osteoporosis screening,
monitoring and diagnosis. Revenio has also identified new growth opportunities
in healthcare technology whose common denominators are screening, monitoring,
and the global need to achieve cost savings in healthcare through preventive
measures. Revenio seeks vigorous growth in healthcare technology, both
organically and through acquisitions and mergers.

In 2013, the Revenio Group's net sales totaled EUR 25.7 million, with its
operating margin standing at 21.7%. The Revenio Group Corporation is listed on
NASDAQ OMX Helsinki.


[HUG#1890870]